<DOC>
	<DOCNO>NCT02394470</DOCNO>
	<brief_summary>The purpose study validate non-invasive user-friendly method monitor systemic pulmonary congestion heart failure patient . The primary objective validate role bioimpedentiometry , pulmonary subcutaneous ultrasound , ass change total body water patient heart failure . v gold standard technique deuterium oxide dilution Secondary objectives - evaluate applicability bioimpedentiometry , pulmonary subcutaneous ultrasound monitor systemic , pulmonary peripheral district congestion relation clinical laboratory variable ; 2 ) analyze organizational issue relate use method .</brief_summary>
	<brief_title>BioImpedentiometry , Lung UltraSound cONgestion Heart Failure</brief_title>
	<detailed_description>Increased congestion lead clinical manifestation heart failure ( dyspnea , peripheral edema ) consider lead cause hospital admission death among patient HF Preclinical recognition congestion HF patient home monitoring crucial prevent acute exacerbation hospital admission . Daily body weight , vital sign fluid balance give indirect assessment level congestion . Deuterium oxide dilution non-invasive reference method total body water assessment . Bioelectrical impedance analysis ( BIA ) chest ultrasound simple , non-invasive technique potentially applicable home monitoring congestion non-physicians . BIA noninvasive method study body composition base measurement body electrical resistance ; BIA may allow measurement whole body segmental , e.g . pulmonary , fluid . However data value BIA monitoring HF patient still scarce , inconclusive relative small cohort patient . Lung ultrasound ( LUS ) evaluation B-lines , reverberation artifact presence extravascular lung water propose semiquantitative tool ass pulmonary congestion . B line show good correlation multiple indicator congestion . The aim study validate whole body segmental BIA lung ultrasound v gold standard deuterium dilution technique monitor change systemic pulmonary congestion treatment set acute heart failure ( AHF Group 1 ) advance chronic heart failure ( ad-CHF Group 3 ) use control stable chronic heart failure outpatient ( CHF Group 2 ) . Enrolled patient simultaneously undergo clinical assessment congestion ( weight gain , pulmonary rale , jugular venous pressure , peripheral edema , chest X-ray ) , routine laboratory , BIA pulmonary subcutaneous ultrasound deuterium administration follow Group 1 ( Acute Heart Failure - AHF ) Patients assess within 24 hour admission acute heart failure ( T0 ) , hospital discharge average 10 day ( Td ) . Group 2 ( Chronic Heart Failure - CHF ) Patients assess programmed outpatient visit ( T0 ) 10 ± 3 day ( T1 ) . Group 3 ( Advanced Chronic Heart Failure -Ad-CHF ) Ad-CHF patient periodic levosimendan undergo monthly levosimendan infusion outpatient clinic . Baseline assessment perform day levosimendan administration , infusion start ( T0 ) 80 +/- 12 hour , i.e peak haemodynamic effect levosimendan ( Tp ) . In patient group , vital status hospital admission emergency department visit cause assessed 6 month telephone follow-up .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Deuterium Oxide</mesh_term>
	<criteria>Signed informed consent Groupspecific inclusion criterion : 1 . Group 1 ( Acute Heart Failure AHF ) , patient admit hospital acute heart failure ( denovo exacerbation chronic heart failure ) , least two follow congestion criterion : weight gain ≥ 2 kg three day prior hospitalization physical finding radiographic sign pulmonary congestion ( crackle , semiorthopnea ) Hepatomegaly &gt; 2 cm arch rib ascites jugular turgor central venous pressure &gt; 10 cm H20 Ankle swell 2 . Group 2 ( Chronic Heart Failure CHF ) : outpatient chronic heart failure ( CHF ) character clinical stability No hospitalization previous six month Symptoms stable least 4 week Oral therapy stable least 4 week No involuntary weight variation great 2 kg last 4 week Absence sign congestion 3 . Group 3 ( advanced Chronic Heart Failure adCHF ) Patients optimal medical therapy HF treat periodic infusion levosimendan ( every 4 week ) accord follow criterion Systolic dysfunction ( LVEF &lt; 35 % ) NYHA Class IIIbIV and/or level INTERMACS 4 , 5 , 6 ≥2 admission access emergency department acute HF exacerbation previous 12 month Uremia dialysis treatment Invasive mechanical ventilation Mechanical circulatory support Cardiac cachexia define weight loss ≥ 5 % prior 12 month body mass index &lt; 20 kg/m2 hypoalbuminemia ( albumin &lt; 3.2 g/dl ) anemia ( hemoglobin &lt; 12 g/l )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>congestion</keyword>
	<keyword>total body water</keyword>
	<keyword>bioimpedentiometry</keyword>
	<keyword>lung ultrasound</keyword>
	<keyword>diuretic</keyword>
	<keyword>dyspnea</keyword>
	<keyword>pulmonary B line</keyword>
	<keyword>deuterium</keyword>
</DOC>